Beijing Tiantan Biological Products (600161) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 reached RMB 1.23 billion, with net profit attributable to shareholders at RMB 325.6 million, down 7.44% compared to the same quarter last year.

• Year-to-date revenue was RMB 4.07 billion, up 1.28% year-over-year, and net profit attributable to shareholders was RMB 1.05 billion, up 18.52% year-over-year, driven by higher product sales prices and improved profit margins.

• Cash flow from operating activities in Q3 dropped 91.39% year-over-year, and for the nine-month period, it decreased 44.52%.

Financial highlights

• Basic and diluted EPS for Q3 were RMB 0.16, up 1.57% year-over-year; for the nine months, EPS was RMB 0.53, up 18.52%.

• Total assets at quarter-end were RMB 15.55 billion, up 9.62% from the end of last year.

• Owner's equity attributable to shareholders was RMB 10.64 billion, up 8.33% from year-end 2023.

• Operating profit increased 19.72% year-over-year to RMB 1.73 billion.

• Non-recurring gains for the nine months totaled RMB 8.09 million, mainly from government subsidies.

Key financial ratios and metrics

• Weighted average ROE for Q3 was 3.11%, down 0.29 percentage points year-over-year; for the nine months, it was 10.27%, up 0.67 percentage points.

• Gross margin and other profitability metrics not explicitly disclosed.